COMMUNIQUÉS West-GlobeNewswire

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
03/09/2026
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
03/09/2026
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United [...]
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
03/09/2026
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart [...]
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
03/09/2026
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
ANI Pharmaceuticals to Present at September Investor Conferences
03/09/2026
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the [...]
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
03/09/2026
ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with [...]
Biodesix to Participate in Upcoming Investor Conferences
03/09/2026
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming [...]
Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials
03/09/2026
Cette acquisition apporte au réseau de développement clinique précoce de Fortrea des compétences bioanalytiques dédiées et une capacité accrue alors que Worldwide poursuit sa stratégie visant à renforcer ses activités [...]
Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026
03/09/2026
SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” [...]
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
03/09/2026
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly [...]
Tensive to receive €20 million from EIB to commercialize bioresorbable breast implant
03/09/2026
European Investment Bank (EIB) convertible loan will help fund REGENERA™ development, CE marking, manufacturing scale-up and commercialization Follows positive 12-month pivotal trial data in July First EU regulatory [...]
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
03/09/2026
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in [...]
Commure Ambient AI Achieves Class I Certification and MHRA Registration
03/09/2026
AI-Powered Clinical Documentation Self-Certified for Immediate UK and EU Deployment MOUNTAIN VIEW, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Commure today announced that Commure Ambient AI , its widely deployed AI [...]
ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury
03/09/2026
The EIGER study will assess the safety and preliminary effectiveness of the investigational ARC-IM ® System to restore mobility after both subacute and chronic spinal cord injury ARC-IM is an implanted neuromodulation [...]
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
03/09/2026
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai [...]
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
03/09/2026
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese ( [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
02/09/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
02/09/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
02/09/2026
Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( [...]

Pages